HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Tsukasa Teshima Selected Research

cilnidipine

1/2021Single-pill combination of cilnidipine, an l-/n-type calcium channel blocker, and valsartan reduces the day-by-day variability of morning home systolic blood pressure in patients with treated hypertension: A sub-analysis of the HOPE-combi survey.
8/2020A post-marketing survey evaluating the safety and efficacy of a fixed-dose single-pill combination of cilnidipine and valsartan in patients with hypertension: Real-world JSH 2014 and 2019 implementations.
1/2020Single-pill combination of cilnidipine, an L-/N-type calcium channel blocker, and valsartan effectively reduces home pulse pressure in patients with uncontrolled hypertension and sympathetic hyperactivity: The HOPE-Combi survey.
6/2018Effects of Cilnidipine, an L/N-Type Calcium Channel Blocker, on Carotid Atherosclerosis in Japanese Post-Stroke Hypertensive Patients: Results from the CA-ATTEND Study.
1/2017Blood pressure control with cilnidipine treatment in Japanese post-stroke hypertensive patients: The CA-ATTEND study.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Tsukasa Teshima Research Topics

Disease

3Hypertension (High Blood Pressure)
01/2021 - 01/2020
2Stroke (Strokes)
06/2018 - 01/2017
1Carotid Artery Diseases
06/2018
1Exanthema (Rash)
09/2017
1Hypersensitivity (Allergy)
09/2017
1Interstitial Lung Diseases (Interstitial Lung Disease)
09/2017
1Anaphylaxis (Anaphylactic Shock)
09/2017
1Neutropenia
09/2017

Drug/Important Bio-Agent (IBA)

5cilnidipineIBA
01/2021 - 01/2017
3Valsartan (Vals)FDA Link
01/2021 - 01/2020
3N-Type Calcium Channels (N-Type Calcium Channel)IBA
01/2021 - 06/2018
3Fenofibrate (CiL)FDA LinkGeneric
01/2021 - 01/2020
1SympatholyticsIBA
01/2020
1Filgrastim (Neupogen)FDA Link
09/2017
1Pharmaceutical PreparationsIBA
09/2017
1Antihypertensive Agents (Antihypertensives)IBA
01/2017

Therapy/Procedure

1Drug Therapy (Chemotherapy)
09/2017